netFormulary South East London Joint Medicines Formulary NHS
Guy's and St Thomas' NHS Foundation Trust
Kings College Hospital NHS Foundation Trust
Lewisham and Greenwich NHS Trust
 
 Search
 Formulary Chapter 11: Eye - Full Chapter
11.08.02  Expand sub section  Ocular diagnostic and peri-operative preparations and photodynamic treatment
11.08.02  Expand sub section  Ocular diagnostic preparations
11.08.02  Expand sub section  Ocular peri-operative drugs
11.08.02  Expand sub section  Subfoveal choroidal neovascularisation
Aflibercept intravitreal injection

View adult BNF  View SPC online
Formulary
High Cost Medicine
Red
Approved as per NICE technology appraisal guidance

Link  NICE TA294: Macular degeneration (wet age-related) - aflibercept
Link  NICE TA305: Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion
Link  NICE TA346: Aflibercept for treating diabetic macular oedema
Link  NICE TA409: Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion
Link  NICE TA486: Aflibercept for treating choroidal neovascularisation    
Ranibizumab intravitreal injection

View adult BNF  View SPC online
Formulary
High Cost Medicine
Red

Link  NICE TA155: Ranibizumab and pegaptanib for the treatment of age-related macular degeneration
Link  NICE TA274: Macular oedema (diabetic) - ranibizumab
Link  NICE TA283: Macular oedema (retinal vein occlusion) - ranibizumab: guidance
Link  NICE TA298: Choroidal neovascularisation (pathological myopia) - ranibizumab    
Verteporfin injection

View adult BNF  View SPC online
Formulary
High Cost Medicine
Red

Link  NICE TA68: Guidance on the use of photodynamic therapy for age-related macular degeneration    
Verteporfin injection

View adult BNF  View SPC online
Formulary
High Cost Medicine
Red
Approved off-label use:
Treatment of chronic central serous chorio-retinopathy (CSC)
Restricted to Consultant Specialists in medical retinal disease
   
Bevacizumab intravitreal injection (1.25 mg in 0.05 mL)

View adult BNF  View SPC online
Restricted Drug Unlicensed
Red
Approved for:
  • Neovascular glaucoma
  • Rubeosis iridis (iris neovascularisation) not responding to conventional treatment
  • Use prior to vitrectomy surgery in severe proliferative diabetic retinopathy
  •    
    11.08.02  Expand sub section  Vitreomacular traction to top
     ....
    Key
    note Notes First Choice Item First Choice item
    Section Title Section Title (top level) Non Formulary Item Non Formulary section
    Section Title Section Title (sub level)
    Cytotoxic Drug
    Cytotoxic Drug
    Restricted Drug
    Restricted Drug
    CD
    Controlled Drug
    Unlicensed Drug
    Unlicensed
    High Cost Medicine
    High Cost Medicine
    click to search medicines.org.uk
    Link to SPCs
    click to search medicines.org.uk
    Link to adult BNF
    Track Changes
    Display tracking information
    click to search medicines.org.uk
    Cancer Drugs Fund
    Cancer Drugs Fund
       

     

    Traffic Light Status Information

    Status Description
      Red   Specialist Prescribing only. The responsibility for prescribing, monitoring, dose adjustment and review should remain with the specialist. In very exceptional circumstances a specialist may discuss individual patient need for a RED drug to be prescribed by a GP and the GP should consider informing the Medicines Management team before a decision is made to prescribe for individual patients.   
      Amber 1   Treatment can be initiated in primary care after a recommendation from an appropriate specialist  
      Amber 2   Specialist initiation followed by maintenance prescribing in primary care  
      Amber 3   Specialist initiation with ongoing monitoring required. After dose stabilisation GPs can be requested to take over prescribing responsibilities using the approved APC shared care documentation  
      Green   Specialist and non-specialist initiation  
      Grey   Not recommended for prescribing  

    netFormulary